Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

NCT03821233 is registered in ClinicalTrials.gov with Zymeworks BC Inc. as lead sponsor.

NCT NCT03821233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03821233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Lead sponsor
Zymeworks BC Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 15, 2019
Completion date
October 8, 2024
Enrollment
112 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

her2-expressing cancers